ChemoCentryx Inc Stock Research

CCXI Stock Price

CCXI RSI Chart

CCXI Valuation

Market Cap

3.7B

Price/Earnings (Trailing)

-27.87

Price/Sales (Trailing)

99.5

Price/Free Cashflow

-62.9

CCXI Price/Sales (Trailing)

CCXI Profitability

Operating Margin

94.59%

Return on Equity

-56.27%

Return on Assets

-31.74%

Free Cashflow Yield

-1.59%

CCXI Fundamentals

CCXI Revenue

Revenue (TTM)

37.3M

Revenue Y/Y

548.81%

Revenue Q/Q

115.48%

CCXI Earnings

Earnings (TTM)

-133.1M

Earnings Y/Y

19.28%

Earnings Q/Q

18.02%

Price Action

Last 7 days

0.1%

Last 30 days

0.8%

Last 90 days

121.2%

Trailing 12 Months

54.5%

CCXI Financial Health

Current Ratio

4.54

Debt/Equity

0.1

Debt/Cashflow

-2.26

CCXI Investor Care

Shares Dilution (1Y)

2.09%

Peers (Alternatives to ChemoCentryx)

View All Peers In Detail

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
BGNE	292.3B	1.4B	-2.86%	5.92%	-145.87	206.43	20.37%	-37.45%
ABBV	282.2B	58.1B	2.61%	-0.83%	23.85	4.86	3.30%	2.55%
REGN	87.8B	12.2B	6.72%	17.20%	20.25	7.22	-24.26%	-46.28%
VRTX	81.0B	8.9B	7.53%	21.69%	24.38	9.07	17.91%	41.84%
ALNY	24.8B	1.0B	1.92%	18.08%	-21.95	23.93	22.88%	-32.64%
SRPT	12.1B	933.0M	11.38%	73.09%	-17.23	12.99	32.93%	-67.99%
UTHR	10.3B	1.9B	-10.99%	24.69%	14.17	5.32	14.88%	52.86%
MID-CAP
MDGL	4.4B	504.0K	-13.39%	136.08%	-14.85	2.5K	-66.53%	-22.12%
RARE	2.8B	363.3M	-13.15%	-45.85%	-3.98	7.75	3.39%	-55.81%
BPMC	2.7B	204.0M	4.53%	-31.92%	-4.84	13.22	13.30%	13.44%
MRTX	2.2B	12.4M	-19.96%	-55.91%	-2.9	172.97	-	-27.34%
SMALL-CAP
CPRX	1.7B	214.2M	7.86%	98.79%	21.01	8.15	52.10%	110.42%
MGNX	442.4M	151.9M	16.91%	-19.64%	-3.69	2.91	96.19%	40.75%
CRBP	30.3M	-	195.32%	1625.28%	-0.72	19.11	-77.61%	7.22%
CYTK	3.3M	94.6M	-21.10%	-6.35%	-0.01	0.03	34.30%	-80.65%

Financials for ChemoCentryx

* denotes actual numbers (not divided by Thousands)
Income Statement (Last 12 Months)					(In Thousands)
Description	(%) Q/Q	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2
Revenue	36.4%	37,280	27,330	32,224	34,267	21,609
S&GA Expenses	9.6%	97,081	88,600	78,851	68,270	59,034
R&D Expenses	-8.4%	70,550	77,048	82,990	85,446	84,080
Costs and Expenses	1.7%	168,941	166,155	162,143	153,716	143,114
Interest Expenses	-4.2%	2,494	2,603	2,695	2,752	2,784
Net Income	5.4%	-133,094	-140,652	-131,755	-121,103	-122,856
Net Income Margin	-10.8%	-3.57*	-3.22*	-2.63*	-	-
Free Cahsflow	-10.0%	-58,969	-53,587	-94,641	-	-

* denotes actual numbers (not divided by Millions)
Balance Sheet					(In Millions)
Description	(%) Q/Q	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2
Assets	-4.8%	419	440	426	455	468
Current Assets	-1.8%	345	352	269	293	317
Cash Equivalents	9.4%	44.00	41.00	50.00	94.00	78.00
Inventory	89.0%	5.00	3.00	1.00	-	-
Net PPE	-2.0%	31.00	31.00	32.00	33.00	34.00
Liabilities	0.6%	183	182	140	139	137
Current Liabilities	10.6%	76.00	69.00	63.00	60.00	55.00
Long Term Debt	0.1%	24.00	24.00	24.00	24.00	25.00
LT Debt, Current	3.1%	20.00	19.00	19.00	14.00	13.00
LT Debt, Non Current	-12.1%	4.00	5.00	5.00	10.00	12.00
Shareholder's Equity	-8.6%	237	259	286	316	330
Retained Earnings	-4.8%	-687	-655	-617	-576	-554
Additional Paid-In Capital	1.1%	926	916	904	892	885
Accumulated Depreciation	-	9.00	-	-	-	-
Shares Outstanding	0.3%	71.00	71.00	70.00	70.00	70.00
Float	-	387	-	-	-	-

Cashflow (Last 12 Months)					(In Millions)
Description	(%) Q/Q	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2
Cashflow From Operations	-18.3%	-53.50	-45.22	-75.62	-83.96	-74.80
Share Based Compensation	1.3%	32.00	32.00	31.00	30.00	29.00
Cashflow From Investing	22.7%	13.00	10.00	92.00	120	-184
Cashflow From Financing	16.0%	8.00	7.00	1.00	1.00	4.00

Risks for CCXI

What is the probability of a big loss on CCXI?

100%

Probability that ChemoCentryx stock will be more than 20% underwater in next one year

73.8%

Probability that ChemoCentryx stock will be more than 30% underwater in next one year.

62.3%

Probability that ChemoCentryx stock will be more than 40% underwater in next one year.

*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does CCXI drawdown profile look like?

Y-axis is the maximum loss one would have experienced if ChemoCentryx was unfortunately bought at previous high price.

Drawdowns

Returns for CCXI

Cumulative Returns on CCXI

16.8%

10-Year Cumulative Returns

33.5%

7-Year Cumulative Returns

49.2%

5-Year Cumulative Returns

88.7%

3-Year Cumulative Returns

What are the long-term rolling returns for CCXI?

FIve years rolling returns for ChemoCentryx.

Annualized Returns

Which funds bought or sold CCXI recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
2023-03-29	Diametric Capital, LP	sold off	-100	-510,000	-	-%
2023-03-23	MetLife Investment Management, LLC	sold off	-100	-1,711,750	-	-%
2023-03-10	VICTORY CAPITAL MANAGEMENT INC	sold off	-100	-548,000	-	-%
2023-03-06	Rockefeller Capital Management L.P.	sold off	-100	-3,000	-	-%
2023-02-28	Voya Investment Management LLC	sold off	-100	-1,253,000	-	-%
2023-02-24	SRS Capital Advisors, Inc.	sold off	-100	-1,000	-	-%
2023-02-24	NATIXIS	sold off	-100	-5,132,000	-	-%
2023-02-21	MACQUARIE GROUP LTD	sold off	-100	-77,000	-	-%
2023-02-15	GAMCO INVESTORS, INC. ET AL	sold off	-100	-2,279,000	-	-%
2023-02-15	PUBLIC EMPLOYEES RETIREMENT SYSTEM OF OHIO	sold off	-100	-2,480,000	-	-%

Latest Funds Activity

Are funds buying CCXI calls or puts?

Calls

Puts

Are funds bullish or bearish(Calls - Puts)?

Net Call Options

No. of funds that own CCXI

No. of Funds

ChemoCentryx News

Schedule 13G FIlings of ChemoCentryx

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Sep 12, 2022	fmr llc	-	0	SC 13G/A
Feb 14, 2022	ra capital management, l.p.	0.0%	0	SC 13G/A
Feb 14, 2022	schall thomas j.	6.5%	4,525,787	SC 13G/A
Feb 09, 2022	vanguard group inc	7.28%	5,098,980	SC 13G/A
Feb 09, 2022	fmr llc	-	0	SC 13G/A
Feb 03, 2022	blackrock inc.	6.2%	4,326,487	SC 13G/A
Oct 14, 2021	vifor (international) ltd	2.7%	1,860,752	SC 13D/A
Jun 09, 2021	wellington management group llp	0.69%	482,747	SC 13G/A
Feb 16, 2021	schall thomas j.	6.3%	4,337,412	SC 13G/A
Feb 16, 2021	ra capital management, l.p.	6.9%	4,776,548	SC 13G/A

CCXI Fair Value

Latest Insider Trading transactions for CCXI

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
2022-10-20	Butt Tausif	back to issuer	-	-	-10,870	evp, chief operating officer
2022-10-20	Parker Geoffrey M.	back to issuer	-	-	-107,997	-
2022-10-20	Cappel Markus J.	back to issuer	-	-	-87,658	chief bus. officer & treasurer
2022-10-20	KANAYA SUSAN M	back to issuer	-	-	-132,717	see remarks
2022-10-20	KANAYA SUSAN M	back to issuer	-	-	-91,317	see remarks
2022-10-20	FECZKO JOSEPH M	back to issuer	-	-	-148,127	-
2022-10-20	Tyree James L	back to issuer	-	-	-9,138	-
2022-10-20	Schall Thomas J.	back to issuer	-	-	-2,393,350	president and ceo
2022-10-20	Edwards Thomas A.	back to issuer	-	-	-143,306	-
2022-10-20	Parker Geoffrey M.	back to issuer	-	-	-21,076	-

About ChemoCentryx

Thomas J. Schall

www.chemocentryx.com

180

ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis. The company also develops TAVNEOS for the treatment of patients with severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy, and lupus nephritis. In addition, it develops CCX559, an orally administered inhibitor for programmed death protein 1/programmed death-ligand 1 for the treatment of various cancers; and CCX507, an orally administered inhibitor of the chemokine receptor known as CCR9, which has completed Phase I clinical trial for the treatment of inflammatory bowel disease. Further, the company has early-stage drug candidates that targets Th17 driven diseases and CCR6. ChemoCentryx, Inc. was incorporated in 1996 and is headquartered in San Carlos, California.

CCXI Income Statement

2022-06-30

Condensed Consolidated Statements of Operations (unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Revenue:
Product Sales Net	$ 9,093	$ 0	$ 14,446	$ 0
Product Supply Sales to Related Party	866	0	866	0
Collaboration and license revenue from related party	1,804	1,699	1,910	11,922
Grant revenue	0	114	0	244
Total revenue	11,763	1,813	17,222	12,166
Operating expenses:
Cost of Sales	803	0	1,008	0
Research and development	14,355	20,853	31,831	44,271
Selling, General and Administrative	28,179	19,698	54,190	35,960
Total operating expenses	43,337	40,551	87,029	80,231
Loss from operations	(31,574)	(38,738)	(69,807)	(68,065)
Other expense:
Interest income	509	224	731	529
Interest expense	(586)	(695)	(1,183)	(1,384)
Total other expense, net	(77)	(471)	(452)	(855)
Net loss	$ (31,651)	$ (39,209)	$ (70,259)	$ (68,920)
Basic and diluted net loss per common share	$ (0.44)	$ (0.56)	$ (0.99)	$ (0.99)
Shares used to compute basic and diluted net loss per common share	71,234	69,788	71,035	69,698

CCXI Balance Sheet

2022-06-30

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 44,396	$ 49,978
Short-term investments	284,219	214,514
Accounts receivable, net	4,759	411
Accounts receivable from related party	187	43
Inventory	5,474	851
Prepaid expenses and other current assets	6,137	3,380
Total current assets	345,172	269,177
Property and equipment, net	30,856	32,269
Long-term investments	17,551	97,856
Operating lease right-of-use assets	24,359	24,806
Other assets	1,452	1,544
Total assets	419,390	425,652
Current liabilities:
Accounts payable	7,592	6,746
Accrued and other current liabilities	27,744	26,358
Long-term debt, current	19,720	18,920
Deferred revenue from related party	21,022	10,993
Total current liabilities	76,078	63,017
Long-term debt, net	4,005	4,715
Non-current deferred revenue from related party	57,299	24,772
Non-current lease liabilities	45,243	46,830
Other non-current liabilities	235	198
Total liabilities	182,860	139,532
Commitments (Note 7)
Stockholders’ equity:
Preferred stock, $0.001 par value, 10,000,000 shares authorized; no shares issued and outstanding	0	0
Common stock, $0.001 par value, 200,000,000 shares authorized; 71,344,838 and 70,357,557 shares issued and outstanding at June 30, 2022 and December 31, 2021, respectively	71	70
Additional paid-in capital	926,141	903,646
Note receivable	(16)	(16)
Accumulated other comprehensive loss	(2,310)	(483)
Accumulated deficit	(687,356)	(617,097)
Total stockholders’ equity	236,530	286,120
Total liabilities and stockholders’ equity	$ 419,390	$ 425,652